Frequent oral pathologies in adults with fixed orthodontic appliances. Literature review

Introducción. La mucosa oral es un lugar de fácil acceso y para el desarrollo de diversas patologías ya sea de origen localizado o generalizado, debido a que, la mayor parte de las enfermedades de la mucosa oral conllevan implicaciones a microorganismos oportunistas de carácter ambulatorio u hospitalario; de tal manera, estas patologías orales presentadas en adultos portadores de aparatología ortodóncica podría crear condiciones favorables para el incremento de la placa bacteriana incluidos los patógenos periodontales con repercusiones sistémicas. Objetivo.  Determinar las patologías orales frecuentes que se presentan en adultos portadores de aparatología ortodóncica fija. Metodología.  La literatura se seleccionó mediante una búsqueda en las bases de datos electrónicas científicas: PubMed, Scopus, Google Academic, Dialnet, ProQuest, Pesquisa, Epistemonikos, Taylor & Francis, sin límite de idioma y con temporalidad desde junio del año 2013 a junio del año 2023. Resultados. Se obtuvo un total de N=1523 de los cuales, la presente revisión de literatura analizó 17 artículos que cumplieron con los criterios de inclusión y poseían evidencia adecuada para ser incorporados en la revisión. Conclusión. La literatura disponible reveló que los individuos adultos portadores de aparatología ortodóncica fija podrían presentar durante su tratamiento diversas patologías orales y dentro de las más frecuentes por déficit de higiene oral es posible encontrar gingivitis, periodontitis, caries, descalcificación del esmalte dental, formación de manchas blancas, entre otras. Por otra parte, para minimizar estos riesgos, es fundamental mantener una rigurosa rutina de higiene bucal, que incluya el cepillado regular, el uso de hilo dental y, posiblemente, enjuagues bucales recomendados por el ortodoncista. Además, es crucial asistir a revisiones dentales periódicas para detectar y tratar cualquier problema oral a tiempo. Área de estudio general: Odontología. Área de estudio específica: Ortodoncia. Tipo de estudio:  Artículo de revisión.Introduction. The oral mucosa is an easily accessible site for the development of various pathologies, whether of localized or generalized origin, since most oral mucosal diseases have implications for opportunistic microorganisms of ambulatory or hospitalized character; thus, these oral pathologies presented in adults wearing orthodontic appliances could create favorable conditions for the increase of bacterial plaque, including periodontal pathogens with systemic repercussions. Objective. To determine the frequent oral pathologies that occur in adults with fixed orthodontic appliances. Methodology. The literature was selected through a search in the electronic scientific databases: Pubmed, Scopus, Google Academic, Dialnet, Proquest, Pesquisa, Epistemonikos, Taylor & Francis, with no language limit and a time frame from June 2013 to June 2023. Results. A total of N = 1523 was obtained, of which the present literature review analyzed 17 articles that met the inclusion criteria and had adequate evidence to be included in the review. Conclusion. The available literature revealed that adult individuals with fixed orthodontic appliances may present various oral pathologies during their treatment, and among the most frequent pathologies due to poor oral hygiene are gingivitis, periodontitis, caries, decalcification of the dental enamel, and the formation of white spots, among others. On the other hand, to minimize these risks, it is essential to maintain a rigorous oral hygiene routine, including regular brushing, flossing, and mouthwashes recommended by the orthodontist. In addition, it is crucial to attend regular dental checkups to detect and treat any oral problems early

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These studies have identified recurrent somatic mutations in NOTCH1, SF3B1, ATM, TP53, BIRC3 and others genes that play roles in cell cycle, DNA repair, RNA metabolism and splicing. In this study, we have taken a deep-targeted massive sequencing approach to analyze the impact of mutations in the most frequently mutated genes in patients with CLL enrolled in the REM (rituximab en mantenimiento) clinical trial. The mutational status of our patients with CLL, except for the TP53 gene, does not seem to affect the good results obtained with maintenance therapy with rituximab after front-line FCR treatment

Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients

The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case-control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p <.001) and at 6 months (63.4% vs. 90.1%, p <.001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p =.001) and 6 months (p <.001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17-83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03-1.36), and therapy with renin-angiotensin-aldosterone system inhibitors (OR = 7.11, 95% CI: 1.47-34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline

He II λ4686 in η Carinae: Collapse of the wind-wind collision region during periastron passage

The periodic spectroscopic events in η Carinae are now well established and occur near the periastron passage of two massive stars in a very eccentric orbit. Several mechanisms have been proposed to explain the variations of different spectral features, such as an eclipse by the wind-wind collision (WWC) boundary, a shell ejection from the primary star or accretion of its wind onto the secondary. All of them have problems explaining all the observed phenomena. To better understand the nature of the cyclic events, we performed a dense monitoring of η Carinae with five Southern telescopes during the 2009 low-excitation event, resulting in a set of data of unprecedented quality and sampling. The intrinsic luminosity of the He II λ4686 emission line (L 310 L) just before periastron reveals the presence of a very luminous transient source of extreme UV radiation emitted in the WWC region. Clumps in the primary's wind probably explain the flare-like behavior of both the X-ray and He II λ4686 light curves. After a short-lived minimum, He II λ4686 emission rises again to a new maximum, when X-rays are still absent or very weak. We interpret this as a collapse of the WWC onto the "surface" of the secondary star, switching off the hard X-ray source and diminishing the WWC shock cone. The recovery from this state is controlled by the momentum balance between the secondary's wind and the clumps in the primary's wind.Facultad de Ciencias Astronómicas y Geofísica

He II λ4686 in η Carinae: Collapse of the wind-wind collision region during periastron passage

The periodic spectroscopic events in η Carinae are now well established and occur near the periastron passage of two massive stars in a very eccentric orbit. Several mechanisms have been proposed to explain the variations of different spectral features, such as an eclipse by the wind-wind collision (WWC) boundary, a shell ejection from the primary star or accretion of its wind onto the secondary. All of them have problems explaining all the observed phenomena. To better understand the nature of the cyclic events, we performed a dense monitoring of η Carinae with five Southern telescopes during the 2009 low-excitation event, resulting in a set of data of unprecedented quality and sampling. The intrinsic luminosity of the He II λ4686 emission line (L 310 L) just before periastron reveals the presence of a very luminous transient source of extreme UV radiation emitted in the WWC region. Clumps in the primary's wind probably explain the flare-like behavior of both the X-ray and He II λ4686 light curves. After a short-lived minimum, He II λ4686 emission rises again to a new maximum, when X-rays are still absent or very weak. We interpret this as a collapse of the WWC onto the "surface" of the secondary star, switching off the hard X-ray source and diminishing the WWC shock cone. The recovery from this state is controlled by the momentum balance between the secondary's wind and the clumps in the primary's wind.Facultad de Ciencias Astronómicas y Geofísica

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P <.05) and less refractoriness (4.5% vs 14.1%; P <.05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P <.05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P <.001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX

Inclusión. Aula Estable con alumnos con discapacidad intelectual: perfil y desarrollo de los alumnos. Una propuesta para alumnos/as del Grado de Pedagogía

Memoria del Proyecto de Innovación docente número 221, de la convocatoria 2019/20 (continuación del Proyecto 41 de la anterior convocatoria)